Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43876   clinical trials with a EudraCT protocol, of which   7294   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2012-005287-10
    Sponsor's Protocol Code Number:2012-PT023
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2021-01-21
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2012-005287-10
    A.3Full title of the trial
    A Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer
    Studio di fase III, in doppio cieco e controllato con placebo su Xilonix™ finalizzato al miglioramento della sopravvivenza nel carcinoma colorettale metastatico
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A study of Xilonix™ for Improving Survival in Colorectal Cancer
    Studio per valutare il farmaco Xilonix™ nel miglioramento della sopravvivenza dei pazienti affetti da carcinoma metastatico del colon-retto
    A.3.2Name or abbreviated title of the trial where available
    A study of Xilonix™ for Improving Survival in Colorectal Cancer
    Studio Clinico con Xilonix™ per migliorare la sopravvivenza dei pazienti con carcinoma del colon-ret
    A.4.1Sponsor's protocol code number2012-PT023
    A.5.2US NCT (ClinicalTrials.gov registry) numberNCT01767857
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorXBIOTECH GERMANY GMBH
    B.1.3.4CountryGermany
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportXBiotech USA, Inc.
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationXBiotech USA, Inc.
    B.5.2Functional name of contact pointClinical Trial Information
    B.5.3 Address:
    B.5.3.1Street Address8201 E Riverside Drive, Building 4, Suite 100
    B.5.3.2Town/ cityAustin
    B.5.3.3Post code78744
    B.5.3.4CountryUnited States
    B.5.4Telephone number0015123862900
    B.5.5Fax number0015123865505
    B.5.6E-mailinfo@xbiotech.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameXilonix™
    D.3.2Product code [NA]
    D.3.4Pharmaceutical form Concentrate for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.9.2Current sponsor codeXilonix
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number50
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboConcentrate for solution for infusion
    D.8.4Route of administration of the placeboIntravenous use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Metastatic Colorectal Cancer
    Carcinoma metastatico del colon-retto
    E.1.1.1Medical condition in easily understood language
    Colorectal cancer
    Tumore maligno del colon-retto
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 21.0
    E.1.2Level LLT
    E.1.2Classification code 10052362
    E.1.2Term Metastatic colorectal cancer
    E.1.2System Organ Class 100000004864
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    Efficacy will be assessed by comparing overall survival (OS) between the MABp1 (plus best supportive care (BSC)) and placebo (plus BSC) groups.
    L'efficacia sarà valutata confrontando la sopravvivenza globale (OS) tra il gruppo MABp1 (associato a migliore terapia di supporto (BSC)) e il gruppo placebo (associato a BSC).
    E.2.2Secondary objectives of the trial
    Change in lean body mass from screening to the cycle 5 assessment and change in quality of life. Other secondary endpoints will be progression-free survival, response rate, disease control rate, and stabilization of platelet counts. LBM will be assessed through the use of dual-energy X-ray absorptiometry (DEXA) scans. Quality of life will be assessed with the EORTC QLQ-C30 (v.3). Response and progression will be evaluated using the Immune Related Response Criteria (irRC).
    Variazione della massa magra dallo screening alla valutazione del ciclo di 5 e cambiamento della qualità della vita. Altri endpoint secondari saranno sopravvivenza libera da progressione, tasso di risposta, tasso di controllo della malattia e stabilizzazione della conta piastrinica. La massa magra (LBM) sarà valutata attraverso l'uso della tecnica di assorbimetria a raggi X a doppia energia (DEXA). La qualità della vita sarà valutata con il questionario EORTC QLQ-C30 (v.3). Risposta e progressione saranno valutati usando i criteri di risposta immunitaria correlati (IRRC).
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Subjects with pathologically confirmed colorectal carcinoma that is metastatic or unresectable and which is refractory to standard therapy. To be considered refractory, a subject must have experienced progression (or intolerance) after treatment with at least all of the following agents: oxaliplatin, irinotecan, flouropyrimidine, and cetuximab or panitumumab if KRAS wildtype.
    2. Subjects will not be treated with any radiation, chemotherapy, or investigational agents while enrolled in this protocol.
    3. Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2.
    4. At least 2 weeks since the last previous cancer treatment including: chemotherapy, radiation therapy, immunotherapy, surgery, hormonal therapy, or targeted biologics and 4 weeks for patients who received treatment immediately prior to the study with anti-IL-1 or anti-TNF agents.
    5. Age = 18 years, male or female subjects.
    6. Serum potassium and magnesium levels within Central Lab normal limits. Total serum calcium or ionized calcium level must be greater than or equal to the lower limit of normal. Subjects with low potassium, calcium and magnesium levels may be replenished to allow for protocol entry.
    7. Adequate renal function, defined by serum creatinine = 1.5 x Central Lab ULN.
    8. Adequate hepatic function defined as:
    • total bilirubin = 1.5 times the Central Lab ULN
    • alanine aminotransferase (ALT) = 2.0 times the Central Lab ULN
    Exception: subjects with known liver metastases: = 3.0 times the institutional ULN for ALT.
    9. Adequate bone marrow function as defined as:
    • absolute neutrophil count (neutrophil and bands) of ¿ 1,500/mm3 (¿ 1.5 x 109/L)
    • platelet count of ¿ 100,000/mm3 (¿ 100 x109/L)
    • hemoglobin of = 9 g/dL
    10. For women of childbearing potential (WOCBP), a negative serum pregnancy test result at Screening and monthly thereafter.
    For women who are not postmenopausal (24 months of amenorrhea) or surgically sterile (absence of ovaries and/or uterus): agreement to use highly effective methods (when used consistently and correctly) of contraception, during the treatment period and for at least 1 month after the last dose of study drug.
    Acceptable highly effectivecontraceptive measures include:
    - Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation: oral, intravaginal or transdermal
    - Progestogen-only hormonal contraception associated with inhibition of ovulation: oral, injectable or implantable
    - Intrauterine device (IUD),
    - Intrauterine hormone-releasing system (IUS)
    - Barrier or sterilization methods: bilateral tubal occlusion, vasectomized partner or sexual abstinence
    For men: agreement to use a barrier method of contraception during the treatment period and for at least 1 month after the last dose of study drug
    11. Signed and dated institutional review board (IRB)-approved informed consent before any protocol-specific screening procedures are performed.
    12. Patients enrolled must, in the Investigator’s judgment, be healthy enough to stay on the clinical trial for three months.
    1. Soggetti affetti da carcinoma colorettale confermato dall'analisi patologica, metastatico o non resecabile e refrattario alla terapia standard. Un soggetto viene ritenuto refrattario se ha manifestato progressione (o intolleranza) dopo il trattamento con almeno tutti i seguenti agenti: oxaliplatino, irinotecan, flouropirimidinae cetuximab o panitumumab (in caso di tumore KRAS wild-type).
    2. Nell'ambito del presente protocollo, i soggetti arruolati non saranno sottoposti a radioterapia o chemioterapia, né saranno trattati con agenti sperimentali.
    3. Stato di performance ECOG (Eastern Cooperative Oncology Group) pari a 0, 1 o 2.
    4. Devono essere trascorse almeno 2 settimane dall'ultimo trattamento antitumorale, tra cui chemioterapia, radioterapia, immunoterapia, intervento chirurgico, terapia ormonale o agenti biologici mirati ed almeno 4 settimane per pazienti che hanno ricevuto il trattamento immediatamente prima dello studio con agenti anti-IL-1 o anti-TNF.
    5. Soggetti di età =18 anni, di sesso maschile o femminile.
    6. Livelli sierici di potassio e magnesio nei limiti della norma del laboratorio Centrale. Il valore sierico totale del calcio o del calcio ionizzato deve essere superiore o uguale al limite inferiore della norma. Ai soggetti che presentano livelli bassi di potassio, calcio e magnesio possono essere somministrati degli integratori per poter accedere al protocollo.
    7. Funzionalità renale adeguata, definita da un livello di creatinina sierica =1,5 × il limite superiore della norma (Upper Limit of Normal, ULN) del Laboratorio Centrale.
    8. Funzionalità epatica adeguata, definita da:
    • bilirubina totale =1,5 volte l'ULN del Laboratorio Centrale
    • alanina aminotransferasi (ALT) =2,0 volte l'ULN istituzionale
    Eccezione - soggetti con metastasi epatiche note: =3,0 volte l'ULN istituzionale per l'ALT.
    9. Funzionalità midollare adeguata, definita da:
    • conta assoluta dei neutrofili (neutrofili e neutrofili a banda) ¿1.500/mm3 (¿1,5 x 109/l)
    • conta piastrinica ¿100.000/mm3 (¿100 x109/l)
    • emoglobina =9 g/dl.
    10. Per le donne potenzialmente fertili, esito negativo del test di gravidanza sul siero allo screening e ad ogni mese successivo.

    Per le donne che non sono in post-menopausa (24 mesi di amenorrea) ne chirurgicamente sterili (assenza di ovaie e / o utero): acconsentire all’utilizzo di metodi di contraccezione altamente efficaci (quando impiegato constantemente e correttamente), durante il periodo di trattamento e per almeno 1 mese dopo l'ultima dose del farmaco in studio.

    Misure contraccettive altamente efficaci accettabili includono:
    - Contraccezione ormonale combinata (a base di estrogeno e progestinico) associata ad inibizione dell'ovulazione: orale, intravaginale o transdermica
    - Contraccezione ormonale a base di solo progestinico associata ad inibizione dell'ovulazione: orale, iniettabile o impiantabile
    - Dispositivo intrauterino (IUD)
    - Sistema dell'ormone di rilascio intrauterino (IUS)
    - Metodi di barriera o sterilizzazione: occlusione bilaterale delle tube, vasectomia del partner o astinenza sessuale
    Per gli uomini: acconsentire all’utilizzo di metodi contraccettivi di barriera durante il periodo di trattamento e per almeno 1 mese dopo l'ultima dose del farmaco in studio.

    11. Consenso informato approvato dalla Commissione di revisione istituzionale (Institutional Review Board, IRB) firmato e datato prima dello svolgimento di qualsiasi procedura di screening specifica del protocollo.
    12. I pazienti arruolati devono essere sufficientemente sani, secondo il giudizio dello sperimentatore, da poter partecipare alla sperimentazione clinica per tre mesi.
    E.4Principal exclusion criteria
    1. Mechanical obstruction that would prevent adequate oral nutritional intake.
    2. Serious uncontrolled medical disorder, or active infection, that would impair the ability of the patient to receive protocol therapy.
    3. Uncontrolled or significant cardiovascular disease, including:
    • A myocardial infarction within the past 6 months.
    • Uncontrolled angina within the past 3 months.
    • Congestive heart failure within the past 3 months, defined as New York Heart Association (NYHA) Classes II or higher.
    • Diagnosed or suspected congenital long QT syndrome.
    • Any history of clinically significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, Wolff-Parkinson-White (WPW) syndrome, or torsade de pointes).
    • Any history of second or third degree heart block (may be eligible if currently have a pacemaker).
    • Uncontrolled hypertension (blood pressure >140 mm Hg systolic and >90 mm Hg diastolic).
    4. Dementia or altered mental status that would prohibit the understanding or rendering of informed consent.
    5. Subjects who have not recovered from the adverse effects of prior therapy at the time of enrollment to = grade 1; excluding alopecia and grade 2 neuropathy.
    6. Immunocompromised subjects, including subjects known to be infected with human immunodeficiency virus (HIV).
    7. Known hepatitis B surface antigen and/or positive hepatitis C antibody and presence of hepatitis C RNA.
    8. History of tuberculosis (latent or active) or known positive Interferon-gamma release assay (IGRA).
    9. Receipt of a live (attenuated) vaccine within 1 month prior to Screening.
    10. Subjects with history of hypersensitivity to compounds of similar chemical or biologic composition of Xilonix™.
    11. Women who are pregnant or breastfeeding.
    12. WOCBP or men whose sexual partners are WOCBP who are unwilling or unable to use an highly effective acceptable method of contraception for at least 1 month prior to study entry, for the duration of the study, and for at least 1 month after the last dose of study medication.
    13. Weight loss >20% in the previous 6 months.
    14. History of progressive multifocal leukoencephalopathy or other demyelinating disease
    15. Subjects on immunosuppressive therapy, including transplant patients
    1. Ostruzione meccanica che impedirebbe un adeguato apporto nutrizionale per via orale.
    2. Infezione attiva o patologia grave non controllata che comprometterebbe la capacità del paziente di ricevere la terapia prevista dal protocollo.
    3. Malattia cardiovascolare non controllata o significativa, tra cui:
    • Infarto del miocardio nei 6 mesi precedenti.
    • Angina non controllata nei 3 mesi precedenti.
    • Insufficienza cardiaca congestizia nei 3 mesi precedenti, definita come di classe II in base alla Classificazione NYHA (New York Heart Association).
    • Diagnosi o sospetto di sindrome del QT lungo congenita.
    • Anamnesi positiva per aritmie ventricolari clinicamente significative (per es. tachicardia ventricolare, fibrillazione ventricolare, sindrome di Wolff Parkinson White [WPW] o torsione di punta).
    • Anamnesi positiva per blocco cardiaco di II o III grado (i pazienti portatori di pacemaker potrebbero essere idonei).
    • Ipertensione non controllata (pressione arteriosa sistolica >140 mm Hg e diastolica >90 mm Hg).
    4. Demenza o alterazione dello stato mentale che impedirebbe la comprensione o l'interpretazione del consenso informato.
    5. Soggetti che, al momento dell'arruolamento, presentano effetti avversi dovuti alla precedente terapia che non si sono risolti a un grado =1 (eccetto alopecia e neuropatia di grado 2).
    6. Soggetti immunocompromessi, ivi inclusi soggetti con infezione nota da virus dell'immunodeficienza umana (HIV).
    7. Positività nota all'antigene di superficie dell'epatite B e/o agli anticorpi anti virus dell'epatite C e presenza dell'RNA dell'epatite C.
    8. Anamnesi positiva per tubercolosi (latente o attiva) o positività nota al saggio di rilascio di interferone-gamma (Interferon-Gamma Release Assay, IGRA).
    9. Vaccinazione con vaccino vivo (attenuato) nel mese precedente allo screening.
    10. Soggetti con anamnesi positiva per ipersensibilità a composti dalla composizione chimica o biologica simile a quella di Xilonix™.
    11. Donne in gravidanza o allattamento.
    12. Donne in età fertile o uomini con partner femminili in età fertile che non sono disposti o non sono in grado di utilizzare un metodo contraccettivo altamente efficace per almeno 1 mese prima dell'ingresso nella sperimentazione, nel corso della stessa e per almeno 1 mese dopo la somministrazione dell'ultima dose del farmaco in studio.
    13. Perdita di peso >20% nei 6 mesi precedenti.
    14. Storia di leucoencefalopatia multifocale progressiva o altre malattie demielinizzanti
    15. Soggetti in terapia immunosoppressiva, inclusi pazienti sottoposti a trapianto.
    E.5 End points
    E.5.1Primary end point(s)
    Overall survival (OS) will be the primary endpoint of this study, which will be measured from the date of randomization until death or last follow-up.
    L'endpoint primario dello studio sarà la sopravvivenza globale (Overall Survival, OS), misurata dalla data della randomizzazione fino al decesso o all'ultimo follow-up.
    E.5.1.1Timepoint(s) of evaluation of this end point
    Date of randomization until death or end of follow-up.
    dalla data della randomizzazione fino al decesso o all'ultimo follow-up.
    E.5.2Secondary end point(s)
    Secondary efficacy variables will include change in lean body mass (LBM) measured by dual-energy X-ray absorptiometry (DEXA) scans, change in Quality of Life assessed through the cancer-specific EORTC QLQ-C30 questionnaire, stabilization of platelet counts, progression free survival (PFS), objective response rate (ORR) and disease control rate (DCR).
    Le variabili secondarie di efficacia includeranno: variazione della massa magra (Lean Body Mass, LBM) misurata mediante assorbimetria a raggi X a doppia energia (Dual-Energy X-Ray Absorptiometry, DEXA), variazioni della qualità della vita valutate attraverso il questionario EORTC QLQ-C30 specifico per il carcinoma, stabilizzazione delle conte piastriniche, sopravvivenza libera da progressione (Progression Free Survival, PFS), tasso di risposta obiettiva (Objective Response Rate, ORR) e tasso di controllo della malattia (Disease Control Rate, DCR).
    E.5.2.1Timepoint(s) of evaluation of this end point
    Date of randomization until death or end of follow-up.
    Dalla data della randomizzazione fino al decesso o all'ultimo follow-up.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned6
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA86
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Argentina
    Australia
    Georgia
    Israel
    Russian Federation
    Serbia
    United States
    Western Sahara
    Austria
    Belgium
    Bulgaria
    Czechia
    France
    Germany
    Ireland
    Italy
    Netherlands
    Poland
    Portugal
    Spain
    Switzerland
    United Kingdom
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    LVLS
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years1
    E.8.9.1In the Member State concerned months10
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years1
    E.8.9.2In all countries concerned by the trial months6
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 360
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 240
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state19
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 413
    F.4.2.2In the whole clinical trial 600
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    None
    Nessuno
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2016-02-09
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2015-10-22
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2017-06-09
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 11 16:19:57 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA